A study to determine if removal of H. pylori (a pathogenic microorganism) can help reduce fat in patients with fatty liver.
Not Applicable
- Conditions
- Health Condition 1: null- Non-alcoholic fatty liver disease
- Registration Number
- CTRI/2017/05/008608
- Lead Sponsor
- Department of Gastroenterology Department of Pharmacology AIIMS New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients of either gender with age > 18 years
2.All patients of NAFLD with H. pylori infection
3.Patients agreeing to sign on the written informed consent document
Exclusion Criteria
Patients with:
1.Cirrhosis
2.Endoscopy proven peptic/ duodenal ulcer(s)
3.History of any other infectious disease at present requiring pharmacotherapy(eg Tuberculosis)
4.History of intake of any of the agents used in H. pylori eradication therapy within past 3 months
5.Patients on anti-arrhythmic drug/ drug(s) having potential to cause QT prolongation
6.History of allergy to any of the components of H. pylori eradication therapy any time in the past
7.Pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in liver fat content measured by transient elastography (FibroScan) with controlled attenuation parameter (CAP)Timepoint: 24 weeks after therapy
- Secondary Outcome Measures
Name Time Method Change in TNF-alfpha, GSH:GSSG ratio, metabolic markers and anthropometric parametersTimepoint: at 12 and/or 24 weeks